Bio

Jan Boesen focuses on deal origination and developing various corporate strategies for the European market. Using his long-term management experience in the biotech and diagnostic industry, he advises on and supports international mergers and acquisitions. Jan Boesen has over 20 years "hands on" experience in the Life Sciences industry of which 16 years were in executive positions. He obtained his Ph.D. degree at Leiden University in 1992. He held various management positions in clinical development, operations and business development at Introgene (now Crucell-J&J). From 1999-2005, Jan Boesen was CEO of Amsterdam Molecular Therapeutics (AMT) B.V. (now UniQure, a publicly trading company). During this period, AMT brought a gene therapy for lipoprotein lipase (LPL) deficiency (Glybera) to the clinic. In 2012, Glybera became the first gene therapy approved by the European Commission. Furthermore, he was General Manager of BioConnection (spin-off from Organon-MSD) and COO of ISA Pharmaceuticals, a company developing therapeutic vaccines. From 2008-2015 he was CEO of IBL International, which develops, produces and sells immunodiagnostics products. During this period, IBL was transformed into a niche player with 50% increased turnover and 86 employees. In July 2014, IBL International was sold to the Tecan Group (Switzerland) for €29 million by Achelous Partners.